.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,759,392

« Back to Dashboard

Details for Patent: 6,759,392

Title: High affinity RNA ligands of basic fibroblast growth factor
Abstract:Methods are described for the identification and preparation of nucleic acid ligand solutions to basic fibroblast growth factor (bFGF). Included in the invention are nucleic acid ligands to bFGF which are inhibitors of bFGF and 2'-amino-modified RNA ligands to bFGF.
Inventor(s): Janjic; Nebojsa (Boulder, CO), Gold; Larry (Boulder, CO)
Assignee: Gilead Sciences, Inc. (Foster City, CA)
Filing Date:May 16, 1995
Application Number:08/442,423
Claims:1. A method for inhibiting angiogenesis comprising administering a pharmaceutically effective amount of a nucleic acid ligand to bFGF, wherein said ligand has an increased affinity to bFGF relative to a total candidate nucleic acid mixture.

2. The method of claim 1 wherein said nucleic acid bFGF ligand is identified according to a method comprising the steps of: a) preparing a candidate mixture of nucleic acids; b) contacting the candidate mixture with bFGF, wherein nucleic acids having an increased affinity to bFGF relative to the total candidate mixture may be partitioned from the remainder of the candidate mixture; c) partitioning the increased affinity nucleic acids from the remainder of the nucleic acids in the candidate mixture; and d) amplifying the increased affinity nucleic acids to yield a mixture of nucleic acids enriched for sequences with increased affinity to bFGF, whereby said nucleic acid ligan is identified.

3. The method of claim 2 wherein said ligand is a 2'-NH.sub.2 -modified ligand selected from the group consisting of SEQ. ID. NOS. 101-165.

4. The method of claim 1 wherein the ligand is a 2'-NH.sub.2 -modified sequence that is substantially homologous to and has substantially the same ability to bind bFGF as the ligands set forth in SEQ. ID. NOS. 101-165.

5. The method of claim 1 wherein the ligand is a 2'-NH.sub.2 -modified sequence that has substantially the same structure as and substantially the same ability to bind bFGF as the ligands set forth in SEQ. ID NOS. 101-165.

6. The method of claim 1 wherein the nucleic acid bFGF ligand is a non-modified sequence selected from the group consisting of SEQ. ID. NOS. 8-22 and 24-69.

7. The method of claim 1 wherein the nucleic acid bFGF ligand is a non-modified sequence that is substantially homologous to and has substantially the same ability to bind bFGF as the ligands set forth in SEQ. ID NOS. 8-22 and 24-69.

8. The method of claim 1 wherein the nucleic acid bFGF ligand is a non-modified sequence that has substantially the same structure as and substantially the same ability to bind bFGF as the ligands set forth in SEQ. ID. NOS. 8-22 and 24-69.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc